Active Med­ical Xcel­lence GmbH (AMX) has suc­cess­fully closed a seven-fig­ure growth financ­ing round. bm‑t beteili­gungs­man­age­ment thürin­gen gmbh (bm|t) par­tic­i­pated as lead investor via the Thuringia Growth Equity Fund II (WBF II). Other investors in the round include Mit­tel­ständis­che Beteili­gungs­ge­sellschaft Thürin­gen mbH (MBG Thürin­gen), Sparkasse Jena-Saale-Hol­z­land, and a busi­ness angel. The financ­ing is intended to enable the fur­ther expan­sion of sales activ­i­ties, inter­na­tional expan­sion, and the con­tin­ued devel­op­ment of AMX’s tech­nol­ogy platform.

Invest­ment in inno­v­a­tive uro­log­i­cal med­ical technology

AMX devel­ops and mar­kets inno­v­a­tive med­ical tech­nol­ogy solu­tions for uro­log­i­cal endoscopy. The com­pany is a spin-off from Active Fiber Sys­tems GmbH and com­bines exper­tise in med­ical tech­nol­ogy, laser tech­nol­ogy, and clin­i­cal urol­ogy. The cur­rent prod­uct port­fo­lio focuses on the MDR-approved active­Cut mor­cel­la­tor, which is used to treat benign pro­sta­tic obstruc­tion and stands out thanks to inte­grated process sup­port, high user-friend­li­ness, and inno­v­a­tive safety features.

With the financ­ing, AMX aims to accel­er­ate the com­mer­cial­iza­tion of active­Cut in Europe and selected inter­na­tional mar­kets. In addi­tion, the com­pany will fur­ther develop its prod­uct pipeline. The goal is to build a com­pre­hen­sive tech­nol­ogy ecosys­tem for uro­log­i­cal endoscopy.

“With our plat­form strat­egy, we aim to sus­tain­ably improve every­day clin­i­cal prac­tice in urol­ogy and pro­vide users with inno­v­a­tive solu­tions for greater safety, effi­ciency, and ease of use. The trust of our investors con­firms the path we have taken and enables us to sig­nif­i­cantly accel­er­ate the com­mer­cial­iza­tion of our tech­nolo­gies,” says Jens Elbrecht, Man­ag­ing Direc­tor and Co-Founder of AMX.

Attrac­tive mar­ket potential

Mar­ket prospects are promis­ing: the global mar­ket for the treat­ment of benign pro­sta­tic hyper­pla­sia is grow­ing steadily due to demo­graphic trends and the increas­ing adop­tion of mod­ern laser-based enu­cle­ation pro­ce­dures. In par­tic­u­lar, pro­ce­dures such as HoLEP and ThuLEP are gain­ing impor­tance inter­na­tion­ally and are increas­ing demand for inno­v­a­tive mor­cel­la­tion solutions.

“AMX com­bines an expe­ri­enced found­ing team with a com­pelling tech­nol­ogy and plat­form strat­egy. The com­pany addresses a grow­ing mar­ket and already has an approved prod­uct with clear dif­fer­en­tia­tors. With this invest­ment, we want to sup­port the company’s fur­ther devel­op­ment while also strength­en­ing Thuringia as a hub for inno­va­tion,” says Ste­fan Jahn, Senior Invest­ment Man­ager at bm|t.

The com­pany, head­quar­tered in Jena, plans to fur­ther expand its orga­ni­za­tion over the com­ing years and cre­ate addi­tional highly qual­i­fied jobs in Thuringia. The financ­ing round there­fore not only con­tributes to the fur­ther devel­op­ment of inno­v­a­tive med­ical tech­nolo­gies, but also strength­ens Thuringia as a cen­ter for research and business.

About Active Medical Xcellence GmbH

Active Med­ical Xcel­lence GmbH, head­quar­tered in Jena, devel­ops inno­v­a­tive med­ical tech­nol­ogy solu­tions for uro­log­i­cal endoscopy. The com­pany com­bines exper­tise in med­ical tech­nol­ogy, laser tech­nol­ogy, and clin­i­cal urol­ogy and pur­sues the goal of improv­ing the treat­ment of uro­log­i­cal dis­eases through intel­li­gent, safe, and user-friendly tech­nolo­gies. The company’s core prod­uct is the MDR-approved active­Cut morcellator.

The investors

About bm|t: bm|t, based in Erfurt, is the lead­ing address for cor­po­rate invest­ments in Thuringia. bm|t cur­rently man­ages twelve funds with a total vol­ume of around 445 mil­lion euros, which invest in inno­v­a­tive com­pa­nies in almost all sec­tors and devel­op­ment phases — whether in the start-up and growth phase or for com­pany suc­ces­sions. Fur­ther infor­ma­tion can be found at: www.bm‑t.de

About Sparkasse Jena-Saale-Hol­z­land: Since 1828, Sparkasse Jena-Saale-Hol­z­land has been rooted in the region and pro­vides finan­cial ser­vices, advi­sory ser­vices, and sup­port pro­grams for com­pa­nies and munic­i­pal­i­ties. As the largest regional finan­cial part­ner, it improves qual­ity of life through dig­i­tal­iza­tion, financ­ing, and pub­lic pro­grams. The sav­ings bank actively sup­ports the econ­omy, edu­ca­tion, sport, and cul­ture in the region. It pro­motes inno­va­tion by sup­port­ing start-ups such as Active Med­ical Xcel­lence GmbH and, together with Busi­ness Angels Club Jena e.V., has cre­ated a plat­form that con­nects start-ups with pri­vate investors to strengthen the regional start-up ecosys­tem. Learn more: www.s‑jena.de

About MBG Thuringia: Mit­tel­ständis­che Beteili­gungs­ge­sellschaft Thürin­gen mbH is a strong and reli­able part­ner for small and medium-sized enter­prises. It offers mez­za­nine and equity invest­ments to strengthen com­pa­nies’ equity base for start-up, growth, or suc­ces­sion solu­tions. This pro­vides com­pa­nies with a solid foun­da­tion for sus­tain­able growth. More infor­ma­tion: www.mbg-thueringen.de